Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Patch Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

NCT02602353
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
Loxoprofen Pain Patch, Placebo Patch, No Treatment
Drug
Lead sponsor
Lead Chemical Co., Ltd.
Industry
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 17, 2026, 11:12 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Traveler's Diarrhea (TD) Automated Process

NCT00751777
View directory record Official record
Conditions
Prevention of Travelers' Diarrhea
Interventions
heat-labile enterotoxin of E. coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Vallejo, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

NCT00206622
View directory record Official record
Conditions
Hot Flashes
Interventions
Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

NCT02324270
View directory record Official record
Conditions
Ankle Sprain
Interventions
Diclofenac epolamine, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
658 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
31
States / cities
Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Results available

Progesterone Augmentation of Nicotine Replacement Therapy Study

NCT02685072
View directory record Official record
Conditions
Smoking Cessation
Interventions
Progesterone (200 mgs BID), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 17, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

NCT01480232
View directory record Official record
Conditions
Nicotine Dependence, Smoking Cessation
Interventions
EVP-6124, Placebo Capsule, NicoDerm Patch (Active), NRT Patch (Placebo), Brief Supportive and Behavioral Treatment
Drug · Behavioral
Lead sponsor
A. Eden Evins
Other
Eligibility
18 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

NCT00306787
View directory record Official record
Conditions
Genital Herpes
Interventions
Famciclovir, Valacyclovir, Placebo matching famciclovir, Placebo matching valacyclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 17, 2026, 11:12 AM EDT
Not listed Phase 2 Interventional

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

NCT04759664
View directory record Official record
Conditions
EGFRI Induced Acneiform Lesions
Interventions
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Glendale, California • Santa Monica, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Results available

Stress Neuroadaptation in Tobacco Dependence

NCT03262233
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine, placebo
Combination Product · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 17, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 17, 2026, 11:12 AM EDT
Terminated Phase 4 Interventional Results available

Use of Transdermal Clonidine in Trauma Patients

NCT01139996
View directory record Official record
Conditions
Delirium
Interventions
Clonidine, Placebo
Drug
Lead sponsor
Memorial Health University Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01640951
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions
AIN457 150 mg, AIN457 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Fresno, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Results available

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

NCT00531947
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Selegiline Transdermal System, Placebo
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • National City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Estradiol Addback

NCT01862835
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Degarelix, Testosterone, Anastrozole, Estrogen patch
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years to 80 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion

NCT02338648
View directory record Official record
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

NCT03210740
View directory record Official record
Conditions
Actinic Keratosis
Interventions
AM001 Cream, 7.5%, Vehicle Cream
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 4 Interventional

Bupropion as an Adjunct to the Nicotine Patch Plus CBT

NCT00142831
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Pharmacotherapies for Smoking Cessation
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
20 Years to 65 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 11:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aromatherapy With Lavender as Anxiolysis Prior to Cataracts Surgery

NCT05708066
View directory record Official record
Conditions
Aromatherapy, Anxiety
Interventions
Lavender Aromatherapy, Non-scented Tab
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 17, 2026, 11:12 AM EDT
Active, not recruiting Early Phase 1 Interventional

Intralesional Cyclosporine for Alopecia Areata

NCT07029204
View directory record Official record
Conditions
Alopecia Areata
Interventions
CycloSPORINE Injectable Product, Saline Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions
SUN-627, Placebo
Drug · Other
Lead sponsor
Sundance Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

CT 327 in the Treatment of Psoriasis Vulgaris

NCT00995969
View directory record Official record
Conditions
Psoriasis
Interventions
placebo, CT 327
Drug
Lead sponsor
Creabilis SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Lidocaine Patches Prior to Intravenous Insertion

NCT00552695
View directory record Official record
Conditions
Need for Intravenous Catheter
Interventions
Lidocaine tetracaine, Placebo
Device
Lead sponsor
Stony Brook University
Other
Eligibility
3 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 17, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

NCT00044070
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
YM872 (zonampanel)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
60
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2006 · Synced Oct 17, 2026, 11:12 AM EDT